Novartis Annual Results

Annual results

Annual Results 2020 - Jan 26, 2021

Media release

English (PDF 0.2 MB)

Deutsch (PDF 0.2 MB)

Français (PDF 0.2 MB)

Condensed financial report (PDF 0.9 MB)

Webcasts and presentations

Press conference

Watch the virtual press conference

Download the press conference presentation (PDF 1.5 MB)

Investors

Watch the investor webcast

Read the presentation transcript

Download the podcast (MP3 45 MB)

Download the investor presentation (PDF 3.6 MB)

Access our interactive slide deck (PDF 12 MB)

 

2020 Annual Reporting Suite

Novartis Annual Review 2020

The Annual Review explains who we are and what we do, and highlights our progress against the company’s five strategic priorities in 2020.

Download the Annual Report 2020 (PDF 3.5 MB)

Visit the 2020 Annual Reporting Suite section

To request a hard copy of the Annual Report and/or SEC Form 20-F, fill out the order form.

2020

Annual Results 2020 - Jan 26, 2021

 

Key figures2 Continuing operations1
  FY 2020
(USD m)		 FY 2019
(USD m)		 % change
(USD/cc)
Net sales 48,659 47,445 3 (cc: 3)
Operating income 10,152 9,086 12 (cc: 19)
Net income 8,071 7,147 13 (cc: 20)
EPS (USD) 3.55 3.12 14 (cc: 21)
Free cash flow 11,691 12,937 -10

Core		      
Operating income 15,416 14,112 9 (cc: 13)
Net income 13,158 12,104 9 (cc: 12)
EPS (USD) 5.78 5.28 9 (cc: 13)

 

  1. Refers to continuing operations as defined on page 43 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions.
  2. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

 

Media release

English (PDF 0.2 MB)

Deutsch (PDF 0.2 MB)

Français (PDF 0.2 MB)

 

Condensed financial report (PDF 0.6 MB)

Watch the webcast

Read the presentation transcript

Download the podcast (MP3 45 MB)

Download the presentation (PDF 3.6 MB)

2019

Annual Results 2019 - Jan 29, 2020

 

Key figures2 Continuing operations1
  FY 2019
(USD m)		 FY 2018
(USD m)		 % change
(USD/cc)
Net sales 47,445 44,751 6 (cc: 9)
Operating income 9,086 8,403 8 (cc: 14)
Net income 7,147 12,800 -44 (cc: -41)
EPS (USD) 3.12 5.52 -43 (cc: -40)
Free cash flow 12,937 11,256 15

Core		      
Operating income 14,112 12,557 12 (cc: 17)
Net income 12,104 10,920 11 (cc: 15)
EPS (USD) 5.28 4.71 12 (cc: 17)

 

  1. Refers to continuing operations as defined on page 45 of the Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz (including the US generic oral solids and dermatology portfolio), as well as the continuing corporate functions.
  2. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 58 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

 

Media release

English (PDF 0.1 MB)

Deutsch (PDF 0.1 MB)

Français (PDF 0.1 MB)

 

Condensed financial report (PDF 0.6 MB)

Read the presentation transcript

Download the podcast (MP3 43 MB)

Download the presentation (PDF 3.6 MB)

2018

Annual Results 2018 - Jan 30, 2019

 

Key figures1 FY 2018
(USD m)		 FY 2017
(USD m)		 % change
(USD/cc)
Net sales 51,900 49,109 6 (cc: 5)
Operating income 8,169 8,629 -5 (cc: -5)
Net income 12,614 7,703 64 (cc: 64)
EPS (USD) 5.44 3.28 66 (cc: 66)
Free cash flow 11,717 10,428 12

Core		      
Operating income 13,823 12,850 8 (cc: 8)
Net income 11,938 11,391 5 (cc: 5)
EPS (USD) 5.15 4.86 6 (cc: 6)

 

  1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 55 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

 

Media release

English (PDF 0.1 MB)

Deutsch (PDF 0.1 MB)

Français (PDF 0.2 MB)

 

Condensed financial report (PDF 0.6 MB)

Read the presentation transcript

Download the podcast (MP3 51 MB)

Download the presentation (PDF 3.4 MB)

XBRL package

Documents Novartis results in XML format in line with requirements of the US Securities and Exchange Commission (SEC).

XBRL Package (ZIP 0.7 MB)

2017

Annual Results 2017 - Jan 24, 2018

 

Key figures1 FY 2017
(USD m)		 FY 2016
(USD m)		 % change
(USD/cc)
Net sales 49,109 48,518 1 (cc: 2)
Operating income 8,629 8,268 4 (cc: 7)
Net income 7,703 6,698 15 (cc: 12)
EPS (USD) 3.28 2.82 16 (cc: 14)
Free cash flow 10,428 9,455 10

Core		      
Operating income 12,850 12,987 -1 (cc: 0)
Net income 11,391 11,314 1 (cc: 2)
EPS (USD) 4.86 4.75 2 (cc: 3)

 

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 42 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.

 

Media release

English (PDF 0.4 MB)

Deutsch (PDF 0.3 MB)

Français (PDF 0.5 MB)

 

Condensed financial report (PDF 0.5 MB)

 

2016

Annual Results 2016 - Jan 25, 2017

 

Continuing operations2
Key figures1 FY 2016
(USD m)		 FY 2015
(USD m)		 % change
(USD/cc)
Net sales 48,518 49,414 -2 (cc: 0)
Operating income 8,268 8,977 -8 (cc: -3)
Net income 6,698 7,028 -5 (cc: 1)
EPS (USD) 2.82 2.92 -3 (cc: 2)
Free cash flow 9,455 9,259 2

Core		      
Operating income 12,987 13,790 -6 (cc: -2)
Net income 11,314 12,041 -6 (cc: -3)
EPS (USD) 4.75 5.01 -5 (cc: -2)

 

1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 50 of the Condensed Financial Report. Unless otherwise noted, all growth rates in this Release refer to same period in prior year.
2. Refers to continuing operations, defined on page 41 of the Condensed Financial Report.

 

Media release

English (PDF 0.4 MB)

Deutsch (PDF 0.4 MB)

Français (PDF 0.4 MB)

 

Condensed financial report (PDF 0.5 MB)

Disclaimer: 

Disclaimer: The information in the presentations on these pages was factually accurate on the date of publication. These presentations remain on the Novartis website for historical purposes only. Novartis assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.

Related Links

Presentations and Events

View recent presentations and learn more about upcoming events

Visit our Event Calendar
 

Contact Investor Relations

Investors International:
Call +41 61 324 79 44

Investors North America:
Call +1 862 778 5052

Novartis Share Registry:
For information relating to the registration of your shares, including name or address changes, please contact us by e‑mail or telephone:
Call +41 61 324 72 04